Crossbridge Bio
AcquiredNext-Generation ADC Therapeutics
Houston, United States · Founded 2023
- Headquarters
- Houston, Texas
- Employees
- 1–10
- Founded
- 2023
- Business Model
- B2B
- Website
- crossbridgebio.com
- Acquisition Date
- Apr 2026
About
CrossBridge Bio is a biotechnology company founded in 2023 and headquartered in Houston, Texas, focused on developing next-generation antibody-drug conjugate (ADC) therapeutics for a range of cancer indications. The company's proprietary stable dual-linker payload technology originated from research at the University of Texas Health Science Center at Houston. CrossBridge Bio was backed by Portal Innovations at its earliest stage and was subsequently acquired by Eli Lilly in a deal worth up to $300 million, announced in April 2026, validating its platform's potential as a differentiated ADC approach.
Summary
Crossbridge Bio is a Biotech company based in Houston, United States, founded in 2023.
Exit History
Apr 2026
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/crossbridge-bio"><img src="https://indexed.vc/api/badge/company/crossbridge-bio" alt="Crossbridge Bio on Indexed.vc" width="260" height="76" /></a>